Trial intelligence / Profile preview

Phase II trial of first-line lazertinib with or without locally ablative radiotherapy for synchronous oligometastatic EGFR-mutant non-small cell lung cancer

KCT0006760Phase 2Completed

Sponsor

Yonsei University Health System

Start

Jan 2022

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1